Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment

Robert L. Boggs, S. Kárpáti, Wenzhi Li, Theresa Williams, Ronald Pedersen, Lotus Mallbris, Robert Gniadecki

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Psoriasis and psoriatic arthritis (PsA) impair quality of life, including reduction in employment or job duties. The PRESTA (Psoriasis Randomized Etanercept STudy in Patients with Psoriatic Arthritis) study, a randomized, double-blind, two-dose trial, examined the efficacy of etanercept treatment in patients with moderate-to-severe plaque psoriasis and PsA and the main results have been presented previously. This analysis examined employment status, job duties and sick days, pre-defined endpoints in PRESTA, among this patient population.Methods: Participants (N = 752) were randomized to receive etanercept 50 mg twice weekly (BIW; n = 379) or 50 mg once weekly (QW; n = 373) for 12 weeks by subcutaneous injection. All participants then received open-label etanercept 50 mg QW for 12 additional weeks, while remaining blinded to the randomization. A pharmacoeconomic questionnaire was administered at baseline, week 12 and week 24 of treatment. The questionnaire included employment status and changing job responsibilities and sick time taken due to psoriasis or PsA. The statistical methods included analysis of covariance, t-test, Fisher's exact test and McNemar's test. Last-observation-carried-forward imputation was used for missing data.Results: Employment was at least maintained from baseline to week 24 in both dose groups (56% [BIW/QW] and 60% [QW/QW] at baseline, 61% and 60%, respectively, at week 24). Among employed participants, the proportion of patients whose job responsibilities changed due to PsA decreased significantly from baseline to week 24 (17-23% to 5-8%; p < 0.01). Similar results were seen with job responsibility changes due to psoriasis (11-14% to 4%; p < 0.01). The number of monthly sick days also decreased from baseline to week 24 (2.4 days for both treatment groups to 0.7 (BIW/QW) and 1.1 (QW/QW); p ≤ 0.03 for each). No significant differences between the treatment groups were observed for any economic endpoint at any time point.Conclusions: For patients with moderate-to-severe plaque psoriasis and PsA, etanercept treatment resulted in reducing job responsibility changes due to disease and in reducing sick time. Effective treatment of psoriasis and PsA may reduce missed work days.

Original languageEnglish
Article number14
JournalBMC Dermatology
Volume14
Issue number1
DOIs
Publication statusPublished - Aug 5 2014

Fingerprint

Psoriatic Arthritis
Sick Leave
Psoriasis
Therapeutics
Pharmaceutical Economics
Subcutaneous Injections
Random Allocation
Etanercept
Economics
Quality of Life
Observation
Population

Keywords

  • Employment
  • Etanercept
  • Pharmacoeconomics
  • Psoriasis
  • Psoriatic arthritis
  • Sick days

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment. / Boggs, Robert L.; Kárpáti, S.; Li, Wenzhi; Williams, Theresa; Pedersen, Ronald; Mallbris, Lotus; Gniadecki, Robert.

In: BMC Dermatology, Vol. 14, No. 1, 14, 05.08.2014.

Research output: Contribution to journalArticle

Boggs, Robert L. ; Kárpáti, S. ; Li, Wenzhi ; Williams, Theresa ; Pedersen, Ronald ; Mallbris, Lotus ; Gniadecki, Robert. / Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment. In: BMC Dermatology. 2014 ; Vol. 14, No. 1.
@article{d37fa39efc86423eae6fc3e8560c0aaa,
title = "Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment",
abstract = "Background: Psoriasis and psoriatic arthritis (PsA) impair quality of life, including reduction in employment or job duties. The PRESTA (Psoriasis Randomized Etanercept STudy in Patients with Psoriatic Arthritis) study, a randomized, double-blind, two-dose trial, examined the efficacy of etanercept treatment in patients with moderate-to-severe plaque psoriasis and PsA and the main results have been presented previously. This analysis examined employment status, job duties and sick days, pre-defined endpoints in PRESTA, among this patient population.Methods: Participants (N = 752) were randomized to receive etanercept 50 mg twice weekly (BIW; n = 379) or 50 mg once weekly (QW; n = 373) for 12 weeks by subcutaneous injection. All participants then received open-label etanercept 50 mg QW for 12 additional weeks, while remaining blinded to the randomization. A pharmacoeconomic questionnaire was administered at baseline, week 12 and week 24 of treatment. The questionnaire included employment status and changing job responsibilities and sick time taken due to psoriasis or PsA. The statistical methods included analysis of covariance, t-test, Fisher's exact test and McNemar's test. Last-observation-carried-forward imputation was used for missing data.Results: Employment was at least maintained from baseline to week 24 in both dose groups (56{\%} [BIW/QW] and 60{\%} [QW/QW] at baseline, 61{\%} and 60{\%}, respectively, at week 24). Among employed participants, the proportion of patients whose job responsibilities changed due to PsA decreased significantly from baseline to week 24 (17-23{\%} to 5-8{\%}; p < 0.01). Similar results were seen with job responsibility changes due to psoriasis (11-14{\%} to 4{\%}; p < 0.01). The number of monthly sick days also decreased from baseline to week 24 (2.4 days for both treatment groups to 0.7 (BIW/QW) and 1.1 (QW/QW); p ≤ 0.03 for each). No significant differences between the treatment groups were observed for any economic endpoint at any time point.Conclusions: For patients with moderate-to-severe plaque psoriasis and PsA, etanercept treatment resulted in reducing job responsibility changes due to disease and in reducing sick time. Effective treatment of psoriasis and PsA may reduce missed work days.",
keywords = "Employment, Etanercept, Pharmacoeconomics, Psoriasis, Psoriatic arthritis, Sick days",
author = "Boggs, {Robert L.} and S. K{\'a}rp{\'a}ti and Wenzhi Li and Theresa Williams and Ronald Pedersen and Lotus Mallbris and Robert Gniadecki",
year = "2014",
month = "8",
day = "5",
doi = "10.1186/1471-5945-14-14",
language = "English",
volume = "14",
journal = "BMC Dermatology",
issn = "1471-5945",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment

AU - Boggs, Robert L.

AU - Kárpáti, S.

AU - Li, Wenzhi

AU - Williams, Theresa

AU - Pedersen, Ronald

AU - Mallbris, Lotus

AU - Gniadecki, Robert

PY - 2014/8/5

Y1 - 2014/8/5

N2 - Background: Psoriasis and psoriatic arthritis (PsA) impair quality of life, including reduction in employment or job duties. The PRESTA (Psoriasis Randomized Etanercept STudy in Patients with Psoriatic Arthritis) study, a randomized, double-blind, two-dose trial, examined the efficacy of etanercept treatment in patients with moderate-to-severe plaque psoriasis and PsA and the main results have been presented previously. This analysis examined employment status, job duties and sick days, pre-defined endpoints in PRESTA, among this patient population.Methods: Participants (N = 752) were randomized to receive etanercept 50 mg twice weekly (BIW; n = 379) or 50 mg once weekly (QW; n = 373) for 12 weeks by subcutaneous injection. All participants then received open-label etanercept 50 mg QW for 12 additional weeks, while remaining blinded to the randomization. A pharmacoeconomic questionnaire was administered at baseline, week 12 and week 24 of treatment. The questionnaire included employment status and changing job responsibilities and sick time taken due to psoriasis or PsA. The statistical methods included analysis of covariance, t-test, Fisher's exact test and McNemar's test. Last-observation-carried-forward imputation was used for missing data.Results: Employment was at least maintained from baseline to week 24 in both dose groups (56% [BIW/QW] and 60% [QW/QW] at baseline, 61% and 60%, respectively, at week 24). Among employed participants, the proportion of patients whose job responsibilities changed due to PsA decreased significantly from baseline to week 24 (17-23% to 5-8%; p < 0.01). Similar results were seen with job responsibility changes due to psoriasis (11-14% to 4%; p < 0.01). The number of monthly sick days also decreased from baseline to week 24 (2.4 days for both treatment groups to 0.7 (BIW/QW) and 1.1 (QW/QW); p ≤ 0.03 for each). No significant differences between the treatment groups were observed for any economic endpoint at any time point.Conclusions: For patients with moderate-to-severe plaque psoriasis and PsA, etanercept treatment resulted in reducing job responsibility changes due to disease and in reducing sick time. Effective treatment of psoriasis and PsA may reduce missed work days.

AB - Background: Psoriasis and psoriatic arthritis (PsA) impair quality of life, including reduction in employment or job duties. The PRESTA (Psoriasis Randomized Etanercept STudy in Patients with Psoriatic Arthritis) study, a randomized, double-blind, two-dose trial, examined the efficacy of etanercept treatment in patients with moderate-to-severe plaque psoriasis and PsA and the main results have been presented previously. This analysis examined employment status, job duties and sick days, pre-defined endpoints in PRESTA, among this patient population.Methods: Participants (N = 752) were randomized to receive etanercept 50 mg twice weekly (BIW; n = 379) or 50 mg once weekly (QW; n = 373) for 12 weeks by subcutaneous injection. All participants then received open-label etanercept 50 mg QW for 12 additional weeks, while remaining blinded to the randomization. A pharmacoeconomic questionnaire was administered at baseline, week 12 and week 24 of treatment. The questionnaire included employment status and changing job responsibilities and sick time taken due to psoriasis or PsA. The statistical methods included analysis of covariance, t-test, Fisher's exact test and McNemar's test. Last-observation-carried-forward imputation was used for missing data.Results: Employment was at least maintained from baseline to week 24 in both dose groups (56% [BIW/QW] and 60% [QW/QW] at baseline, 61% and 60%, respectively, at week 24). Among employed participants, the proportion of patients whose job responsibilities changed due to PsA decreased significantly from baseline to week 24 (17-23% to 5-8%; p < 0.01). Similar results were seen with job responsibility changes due to psoriasis (11-14% to 4%; p < 0.01). The number of monthly sick days also decreased from baseline to week 24 (2.4 days for both treatment groups to 0.7 (BIW/QW) and 1.1 (QW/QW); p ≤ 0.03 for each). No significant differences between the treatment groups were observed for any economic endpoint at any time point.Conclusions: For patients with moderate-to-severe plaque psoriasis and PsA, etanercept treatment resulted in reducing job responsibility changes due to disease and in reducing sick time. Effective treatment of psoriasis and PsA may reduce missed work days.

KW - Employment

KW - Etanercept

KW - Pharmacoeconomics

KW - Psoriasis

KW - Psoriatic arthritis

KW - Sick days

UR - http://www.scopus.com/inward/record.url?scp=84906832735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906832735&partnerID=8YFLogxK

U2 - 10.1186/1471-5945-14-14

DO - 10.1186/1471-5945-14-14

M3 - Article

VL - 14

JO - BMC Dermatology

JF - BMC Dermatology

SN - 1471-5945

IS - 1

M1 - 14

ER -